Ongoing preclinical and clinical studies present compelling data supporting the effectiveness, safety, and favourable tolerability of DNL201, a leucine-rich repeat kinase 2 inhibitor, in restoring lysosomal function in individuals diagnosed with Parkinson's disease, without any unfavourable observations [349]. The gene discussed is LRRK2; the disease is Parkinson disease.